Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

In a case series of eight pediatric patients with systemic lupus erythematosus, dermatomyositis or systemic sclerosis, autologous anti-CD19 CAR T cell therapy was feasible, safe and effective in reducing disease activity.